In the fast paced world of PARP inhibitor approvals in both the setting of maintenance and therapy in ovarian cancer, this panel of experts will assist practitioners to understand how to order germline and somatic testing for BRCA and HRD mutations. Speakers will discuss sequencing of PARP inhibitors as well as mitigating side effects. Additionally, they will discuss future directions for the use of PARP inhibitors as well as briefly discuss resistance to PARP inhibitors.

• Premal Thaker, MD, MS, Washington University in St. Louis Siteman Cancer Center
• Mary (“Maggie”) Mullen, MD, Washington University in St. Louis School of Medicine
• John Farley, MD, COL, FACOG, FACS, Dignity Health - Cancer Institute, St. Joseph's Hospital and Medical Center
• Todd Tillmanns, MD, FACOG, West Cancer Center

REGISTER

This is an educational resource produced through collaboration between the Society of Gynecologic Oncology (SGO) and the Cancer Association of Community Cancer Centers (ACCC).